Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia

Status: Recruiting
Location: See all (4) locations...
Study Type: Observational
SUMMARY

Objective: Reversion of Azacytidine resistance using different drugs targeting apoptosis and/or autophagy. Our laboratory has identified new molecules to selectively induce different types of cell death (apoptosis or autophagy).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• High Risk or Intermediate 2 MDS (IPSS)

• AML-MD (WHO classification)

• Treatment with minimum three to six cycles of Azacitidine

• Informed consent form signed

Locations
Other Locations
France
CH d'Antibes
RECRUITING
Antibes
Centre Antoine Lacassagne
RECRUITING
Nice
CHU de Nice - Hôpital de l'Archet
RECRUITING
Nice
Monaco
CH Princesse Grace
RECRUITING
Monaco
Time Frame
Start Date: 2010-09
Estimated Completion Date: 2025-09
Participants
Target number of participants: 250
Related Therapeutic Areas
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Leukemia
Sponsors
Leads: Centre Hospitalier Universitaire de Nice

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Combining Active and Passive DNA Hypomethylation: A Randomized, Placebo-Controlled Phase II Study of the Efficacy and Safety of Oral Vitamin C in Combination With Azacitidine in Patients With Higher-Risk MDS, CMML-2 or Low-Blast Count AML

Combining Active and Passive DNA Hypomethylation: A Randomized, Placebo-Controlled Phase II Study of the Efficacy and Safety of Oral Vitamin C in Combination With Azacitidine in Patients With Higher-Risk MDS, CMML-2 or Low-Blast Count AML

Who is this study for: Patients with Myelodysplastic Syndromes, Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: April 17, 2024
Intervention Type: Dietary supplement
Study Phase: Phase 2

Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS Overlap or High-Risk CMML

Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS Overlap or High-Risk CMML

Enrollment Status: Recruiting
Publish Date: June 26, 2025
Intervention Type: Biological, Procedure, Drug, Other
Study Phase: Phase 1/Phase 2

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)

Who is this study for: Patients with acute myeloid leukemia or myelodysplastic syndrome
Enrollment Status: Recruiting
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, SL-401, Venetoclax
Study Phase: Phase 1
View All